ISPE SD Logo

 

Industry Update on Cannabidiol Research, Medicinal Uses and How it Translates to the Pharmaceutical Industry

Please Join Us For An Evening Event

ISPE SD 8-22-19 Graphic

Join ISPE San Diego as we dive into discussion with four subject matter experts that are leading the way in the Industry for the safe use of Medicinal Cannabis for patient health

SPECIAL OFFER TO NON-MEMBERS

Join ISPE at the Event and Receive Free Admission For This Meeting


Synopsis:

With the growing search for new drug therapies, Cannabis sativa L has shown promise in delivering a therapeutic effect for epilepsy, and yet 80 more biological active chemical compounds including the best-known compounds, 9-tetrahydrocannabinoil, or THC, and cannabidiol, or CBD are still under research for therapeutic discovery.

With the first ever plant-based cannabinoid to receive FDA approval in 2018, the FDA is advancing sound development programs that properly evaluate and provide scientific evidence that the active ingredients contained in cannabis can safely reach the maximum therapeutic response achievable in a research setting for a beneficial medical discovery. These discoveries have forced regulatory and the life science community to provide more focus on the future involvement of cannabinoids for medicinal use in healthcare. The FDA will continue to support rigorous scientific research on the potential medical uses of cannabis-derived products and is working with product developers and manufacturers who are interested in bringing patients safe and effective, high quality products.

MoldMore LogoMoldMore Logo

Topics to be discussed:

  • CGMP Upstream and Downstream Processing (From Seed to Extraction to Final Packaging)
  • Designing, Implementing and Managing Cleanrooms and Laboratories for Processing  
  • Clinical Research and Requirements 
  • Challenges w/ Safety and Efficacy without regulatory oversight and standardization
  • Current Legislation Movement 

Who Should Attend:

CMOs, CROs, chemists, microbiologists, those working in laboratory analytic processing, regulatory, quality professionals, legal staff and those who are curious about the cannabis industry and the medical use of CBD.

ISO-MED Logo

About The Speakers

Gigi
Dr. Gigi

As VP of strategy and BD, Dr. Gigi is responsible for the corporate development by identifying and shaping CURE’s strategy both organically and inorganically to deliver sustained growth and diversified revenue. She is also responsible for building and maintaining relationships with the pharmaceutical companies, academia and other collaborators. Together with the office of the COO, her charter is to drive operational excellence and competitiveness. Prior to joining CURE, Dr. Gigi was a Project Leader with the Boston Consulting Group. During her tenure, she led and supported a variety of projects at global biopharma and MedTech companies with a focus on corporate and network strategy, operations, marketing and post-merger integration initiatives. Dr. Gigi holds a PhD in Immunology from the University of Pennsylvania and a BSc. in Bio-Medical sciences from Tel-Aviv University in Israel. During her years in academia she investigated immunotherapy, stem cell and DNA repair mechanisms.Vered Gigi PhD, Vice Preseident of Strategy and Business Development, CURE Pharmaceutical


David Grelotti
David Grelotti, Medical Director, University of California Center for Medicinal Cannabis Research

Dr. Grelotti is an Associate Professor of Psychiatry at the University of California San Diego and the Medical Director of the University of California Center for Medicinal Cannabis Research (CMCR). An adult and child psychiatrist, he graduated from medical school at the Johns Hopkins University School of Medicine and completed residency training in the Harvard Medical School Combined Pediatrics, Adult Psychiatry, and Child Psychiatry Residency Training Program at Massachusetts General Hospital and McLean Hospital. With colleagues at the CMCR, he is currently conducting a study of cannabis-related driving impairment, a randomized, placebo-controlled clinical trial of cannabis for low back pain, and investigations of the impact of cannabinoids on the endocannabinoid system in bipolar disorder, HIV, and healthy persons. His research is funded by the National Institutes of Health and the State of California.


Pritesh Kumar, PhD
Pritesh Kumar, PhD, Senior Managing Director, PhytoSciences AG

Dr. Pritesh Kumar earned his PhD in Pharmacology and Toxicology, with a focus in cannabinoid (cannabis) pharmacology, from the University of Louisville, Kentucky. Previously, Dr. Kumar conducted pharmacological testing of FDA- approved drugs as potential ligands for the cannabinoid receptor 2 (CB2) and investigated the pharmacology of cannabinoids.

He is the Senior Managing Director of PhytoSciences AG, a swiss-based consulting firm comprised of 100+ scientists & analysts across the EU, India, Canada, Africa, and USA. The firm advises stakeholders in the areas of clinical trial solutions, novel drug delivery technology development, industrial scale manufacturing, analytical testing, and commercial bioprocessing.

Dr. Kumar is also the Scientific Advisor for Addis Ababa University, School of Pharmacy (SoP) in Ethiopia. In this role, Dr. Kumar facilitates advancements in graduate student education, promotes the interest of the SoP, and develops relationships between the SoP and the private sector.

He previously served as an Advisor to the WHO (World Health Organization) based in Geneva, Switzerland. In this role, Dr. Kumar provided consultation services to the 40th Meeting of the Expert Committee on Drug Dependence regarding Cannabis Toxicology. He was also the Chief Scientific Officer for PharmaCielo Ltd., a Canadian company with operations in Colombia, South America. In this role, he was responsible for the company’s R&D, global business product development strategy, and Phase I development of a state- of-the-art GMP pharmaceutical bioprocessing plant. He was previously the Chair of PharmaCielo’s Research Advisory Board and worked closely with the Medical Advisory Board, headquartered in Geneva, Switzerland, to coordinate clinical programs for cannabinoid-based therapeutics.

He has received numerous honors and awards including Best Oral Presentation from the International Cannabinoid Research Society (ICRS) Conference in Vancouver and fellowships from Drug Discovery and Target in Boston and Integrated Programs in Biomedical Sciences (IPIBS) as well as travel awards from the National Institute on Drug Abuse and University of Louisville School of Medicine for his presentations in the U.S., Canada, Italy, and Germany.

Dr. Kumar has been published in numerous scientific journals including the European Journal of Pharmacology, Pharmacology and Physiology, Journal of Medicinal Chemistry, Investigative Ophthalmology & Visual Science and Biochemical and Biophysical Research Communications.


Michael Rochlin
Michael Rochlin RN, MN- President, Confidential Therapeutics, LLC

Hailing from the San Francisco Bay area, Michael brings a bit of western hospitality to all his clients. He moved to Seattle over thirty years ago after graduating with his undergraduate degree in Nursing from Pennsylvania State University.

He practiced at various Eastern and Western US hospitals and became Charge Nurse at the Cardiac Intensive Care Unit (CICU) of University Washington Medical Center (UWMC). Later he was offered a CDC NIOSH grant and completed a Master's degree in Nursing, Business Administration and Public Health at UW.

Mike relocated to Oregon in 2010, to lead Environmental Health & Safety for the Intel D1X Site Construction project. After that project was completed, he helped OHSU Healthcare remedy their FMLA/ADAAA processes. Mike is a Past-President and Professional member of the Puget Sound Chapter of the American Society of Safety Professionals, member of PNS-American Industrial Hygiene Association, and active research & education committee member of the American Cannabis Nurses Association, as well as Founding Member of the Cannabis Nurses Network. Mike was recently appointed to the Oregon Cannabis Commission Clinical Practice and Training Subcommittee. Michael stays up-to-date on the latest endoCannabinoid Therapeutic scientific discoveries. When not striving to keep his clients happy and healthy, he enjoys exploring scenic wonders of Oregon.


Sponsors

SD Annual Sponsors

DETAILS

REGISTER